New crystallized lithium aims to improve bipolar treatment
Disease control
Recruiting now
This study compares a new crystallized lithium (AL001) to standard lithium carbonate in 20 people with bipolar I disorder. Participants take each drug for 14 days and undergo MRIs and blood tests to measure how lithium enters the brain and body. The goal is to see if AL001 is saf…
Phase: PHASE1, PHASE2 • Sponsor: Alzamend Neuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC